LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Inicio・Lista de Acciones・Editas Medicine Inc

Editas Medicine Inc

Cerrado

SectorSanidad

2.59 2.37

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.58

Máximo

2.68

Métricas clave
By Trading Economics
Ingresos	28M -25M
Ventas	-1.1M 3.6M
Margen de beneficios	-701.984
Empleados	246
EBITDA	23M -49M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+40% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-49M 227M
Apertura anterior	0.22
Cierre anterior	2.59

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

128 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.33 / 1.54 Soporte y Resistencia

Editas Medicine Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 nov 2025, 17:45 UTC

Ganancias

Principales Movimientos del Mercado

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Ganancias

Principales Movimientos del Mercado

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

16 nov 2025, 23:40 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery -- Market Talk

16 nov 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Edge Lower Amid Lingering Worries Over Elevated Tech Valuations -- Market Talk

16 nov 2025, 23:26 UTC

Charlas de Mercado

RBA Policy Meetings May Contain a Trap for Traders -- Market Talk

16 nov 2025, 16:20 UTC

Ganancias

Fed Minutes, Plus Walmart, Target, Home Depot, Nvidia, and More Stocks to Watch This Week -- Barrons.com

15 nov 2025, 09:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

15 nov 2025, 09:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

15 nov 2025, 00:08 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Charlas de Mercado

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Ganancias

Adquisiciones, fusiones, absorciones

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Ganancias

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Charlas de Mercado

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Adquisiciones, fusiones, absorciones

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Charlas de Mercado

Ganancias

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Charlas de Mercado

Ganancias

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Charlas de Mercado

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Charlas de Mercado

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Charlas de Mercado

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

Comparación entre iguales

Cambio de precio

Editas Medicine Inc previsión

Precio Objetivo

By TipRanks

40% repunte

Estimación a 12 Meses

Media 3.64 USD 40%

Máximo 5 USD

Mínimo 1 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Editas Medicine Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Editas Medicine Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.33 / 1.54Soporte y Resistencia

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentimiento

By Acuity

128 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.